How Sensory Nerves Drive Inflammation Through Peptide Release: A Century of Discovery
Sensory nerves actively drive inflammation by releasing neuropeptides like substance P and CGRP, while also releasing anti-inflammatory peptides like somatostatin — a dual role that's now yielding new drug targets.
Quick Facts
What This Study Found
This historical review traces more than a century of research on how sensory nerves drive inflammation — a process called neurogenic inflammation. Sensory nerves don't just detect pain; they actively release peptides that dilate blood vessels and recruit immune cells.
The key neuropeptides identified as drivers of neurogenic inflammation include substance P (which causes vasodilation and plasma leakage) and CGRP (calcitonin gene-related peptide, a potent vasodilator). Sensory nerves also release anti-inflammatory peptides like endogenous opioids and somatostatin, showing the system has built-in brakes. The discovery of TRP channels (particularly TRPV1) revealed how these nerves sense environmental stimuli like heat, chemicals, and injury — providing the molecular mechanism linking tissue damage to neuropeptide release and inflammation.
Key Numbers
How They Did This
Narrative historical review covering research from the initial discovery of sensory nerve function through modern molecular characterization of neuropeptides and TRP channels. Synthesizes findings across vascular biology, pain research, and immunology.
Why This Research Matters
Neurogenic inflammation sits at the crossroads of pain and immune function, and the neuropeptides involved (substance P, CGRP, somatostatin) are now therapeutic targets. CGRP-blocking drugs have already revolutionized migraine treatment, and substance P antagonists are used for chemotherapy-induced nausea. Understanding this century-old field helps explain why peptide-based therapies targeting sensory nerve pathways are among the most promising approaches to inflammatory disease.
The Bigger Picture
This review contextualizes why neuropeptides are now hot therapeutic targets. CGRP-blocking antibodies (like erenumab) transformed migraine treatment, and substance P antagonists (like aprepitant) prevent chemotherapy nausea. Understanding the full landscape of neurogenic inflammation helps explain the rationale behind current and emerging peptide therapies targeting pain, vascular disease, and chronic inflammatory conditions.
What This Study Doesn't Tell Us
As a narrative review, this paper summarizes and interprets existing literature rather than presenting new data. The authors note that despite over a century of research, the precise role of sensory nerves in vascular inflammation versus pain processing remains unclear, highlighting gaps in the field.
Questions This Raises
- ?Can we selectively enhance the anti-inflammatory neuropeptides (somatostatin, opioids) released by sensory nerves while dampening pro-inflammatory ones?
- ?How do TRP channel-targeted therapies compare to directly blocking neuropeptides like CGRP for treating inflammatory conditions?
- ?What role does neurogenic inflammation play in chronic conditions like rheumatoid arthritis or inflammatory bowel disease?
Trust & Context
- Key Stat:
- 100+ years of research Despite over a century of study, the exact role of sensory nerves in vascular inflammation vs. pain processing remains an active area of investigation.
- Evidence Grade:
- This is a narrative review article that synthesizes existing research rather than presenting new experimental data. Reviews are valuable for context and identifying trends but don't generate primary evidence.
- Study Age:
- Published in 2018. The historical perspective and fundamental mechanisms described remain relevant, though the therapeutic landscape (especially CGRP-targeting drugs) has advanced significantly since publication.
- Original Title:
- A historical perspective on the role of sensory nerves in neurogenic inflammation.
- Published In:
- Seminars in immunopathology, 40(3), 229-236 (2018)
- Authors:
- Sousa-Valente, João, Brain, Susan D(2)
- Database ID:
- RPEP-03917
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is neurogenic inflammation?
Neurogenic inflammation is when sensory nerves themselves cause inflammation by releasing peptides like substance P and CGRP into surrounding tissue. Unlike typical immune-driven inflammation, this is triggered directly by nerve activation — from injury, heat, chemicals, or infection — and causes blood vessels to dilate and leak fluid.
How does this relate to modern migraine treatments?
CGRP, one of the key neuropeptides discussed in this review, turned out to be a major driver of migraine. This understanding led to the development of CGRP-blocking antibodies (like erenumab and fremanezumab) and small-molecule CGRP antagonists (gepants), which have become first-line migraine preventives.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-03917APA
Sousa-Valente, João; Brain, Susan D. (2018). A historical perspective on the role of sensory nerves in neurogenic inflammation.. Seminars in immunopathology, 40(3), 229-236. https://doi.org/10.1007/s00281-018-0673-1
MLA
Sousa-Valente, João, et al. "A historical perspective on the role of sensory nerves in neurogenic inflammation.." Seminars in immunopathology, 2018. https://doi.org/10.1007/s00281-018-0673-1
RethinkPeptides
RethinkPeptides Research Database. "A historical perspective on the role of sensory nerves in ne..." RPEP-03917. Retrieved from https://rethinkpeptides.com/research/sousa-valente-2018-a-historical-perspective-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.